PFE Reports earnings results
Summary
Pfizer Inc. furnished its third-quarter 2025 financial results on November 4, 2025, via an Exhibit 99 press release. The company reaffirmed its 2025 Revenue guidance while raising and narrowing its guidance for Adjusted diluted EPS. Pfizer also reached a landmark agreement with the U.S. Government, providing longer-term business clarity, and secured early FTC clearance for its proposed Metsera acquisition to compete in the obesity market.
Why It Matters
Investors should note the raised and narrowed 2025 Adjusted diluted EPS guidance, as this indicates an improved financial outlook. Additionally, the landmark agreement with the U.S. Government and early FTC clearance for the Metsera acquisition signal strategic advancements and potential for future growth in high-growth markets, as highlighted by the CEO (via Ex. 99).
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how PFE traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View PFE Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000078003
- Filing Date
- Tuesday, November 4, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive